Loading…
← CockpitCompetitor Analysis › 688289.SS Sansure Biotech Inc. Class AOpen in the cockpit ↗

Sansure Biotech Inc. Class A688289.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese molecular diagnostics company selling PCR reagents and instruments for infectious-disease and other testing.

≈ A Chinese QIAGEN for molecular (PCR) diagnosticsMomentum strong 63
Mkt cap
$1.24B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$7.32M
20-day average traded
Fwd P/E
35.6×
forward earnings
ROIC−WACC
-2.5 pp
WACC 5.7%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥14.53
1D-1.6%
1W-7.0%
1M-8.9%
3M-13.6%
6M-16.7%
YTD-23.2%
1Y-34.0%
ATR %3.2%
52w lowhigh36.3% off high

What Sansure Biotech does

Chinese molecular diagnostics company selling PCR reagents and instruments for infectious-disease and other testing.

Sells PCR test kits (reagents) plus the machines that run them; because reagents are generally tied to the instruments they run on, an installed instrument keeps pulling reagent orders. Sales jumped during the COVID-19 testing wave of 2020 to 2022 and then fell back as it turned to other disease areas and overseas markets.

In one line: A Chinese QIAGEN for molecular (PCR) diagnostics.

Products and services

  • PCR diagnostic reagents
  • PCR/sequencing instruments
  • Sample preparation consumables

Customers

  • Hospital/CDC laboratories
  • Public health agencies

Where it sits in the supply chain

  • Health Care
  • In-vitro diagnostics
  • Molecular (PCR) diagnostic reagents…

What could go right

  • Infectious-disease testing demand
  • Export expansion

What could go wrong

  • Post-pandemic testing demand normalization

Moat: narrow (installed base, regulatory licence). Instrument-reagent lock-in and disease-testing registrations favor an incumbent supplier.

Headquarters: Changsha, Hunan, China · Employees: 2,128

Named competitors

Sansure Biotech at a glance

Size Sansure Biotech (688289.SS) is a China Health Care company (Medical Specialties) with a market value of $1.24B, the 1795th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.53 on 18 Nov 2026.

Performance Over six months the shares fell 16.7%, against -10.4% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue fell 1.2% over the last twelve months (peer median +13.7%); the operating margin is 1.5% (peer median 11.6%).

Valuation It trades at 35.6× forward earnings against a peer median of 23.9× (5th most expensive of 16).

Capital Return on invested capital runs 2.5 points below its cost of capital (5.7% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 87688289.SS 83
Six months, rebased to 100: Sansure Biotech against the median of its 20 peers (local-currency closes).

Sansure Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.65BCN¥1.64BCN¥1.45BCN¥1.00BCN¥6.42B
Revenue growth—+13%+45%-84%—
Gross profitCN¥1.24BCN¥1.08BCN¥999MCN¥621MCN¥3.69B
EBITDAn/aCN¥364MCN¥296MCN¥119MCN¥2.28B
Net incomeCN¥112MCN¥199MCN¥276MCN¥364MCN¥1.94B
Free cash flow-CN¥109M-CN¥179M-CN¥132M-CN¥279MCN¥2.09B
Capital expenditureCN¥351MCN¥370MCN¥421MCN¥391MCN¥559M
Total debtCN¥1.54BCN¥1.16BCN¥444MCN¥95.4MCN¥27.9M

Quarterly statements and history in the cockpit →

Sansure Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%+20%NVCRSTAA6880502675TNDM300633688758688198688161300406DRTSATECCNMD214150301101PRCT300298688289.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Sansure Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×STAA6880502675300633688758688198300595688161300406ATECCNMD214150688289.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sansure Biotech is the large dot.

Sansure Biotech competitors and peer comparison

Head to head with its named competitors (688289.SS vs QGEN vs 300676.SZ vs 688068.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sansure Biotech 688289.SS$1.24B-17%-1%1%35.6×n/a
Qiagen QGEN$10.2B+41%+2%25%19.5×8.6%
BGI Genomics 300676.SZ$2.13B-15%0%-14%126.7×n/a
Beijing Hotgen Biotech 688068.SS$815M-37%+8%-94%n/an/a

How Sansure Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sansure Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688289.SSPeer medianRank in peer set
1-month return-8.9%-1.7%9th lowest of 21
6-month return-16.7%-10.4%8th lowest of 20
Distance from 52-week high-36.3%-38.5%10th highest of 21
Revenue growth (TTM)-1.2%+13.7%3rd lowest of 19
Operating margin1.5%11.6%5th lowest of 20
Forward P/E35.6×23.9×5th most expensive of 16
ROIC minus cost of capital-2.5 pp+0.2 pp7th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%35.6×n/an/a
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%23.9×10.3%+40.3%
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%120.2×n/an/a
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%

Questions

Who are Sansure Biotech's main competitors?
Named competitors: QIAGEN (QGEN), BGI Genomics (300676.SZ), Beijing Hotgen Biotech (688068.SS). The cockpit's measured peer set (industry) also includes NovoCure (NVCR), STAAR Surgical (STAA), Eyebright Medical Technology (Beijing) (688050.SS), Shenzhen Edge Medical (2675.HK), Tandem Diabetes Care (TNDM), Sonoscape Medical (300633.SZ).
Is Sansure Biotech expensive compared with its peers?
On forward p/e it trades at 35.6× against a peer median of 23.9×, 5th most expensive of 16 in its peer set.
How has Sansure Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -16.7% against -10.4% for the median peer; over one year -34.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.